- Home
- GROW vs CVKD Comparison
GROW vs CVKD Comparison
Compare GROW & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROW
- CVKD
- Stock Information
- Founded
- GROW 1968
- CVKD 2022
- Country
- GROW United States
- CVKD United States
- Employees
- GROW N/A
- CVKD N/A
- Industry
- GROW Investment Managers
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- GROW Finance
- CVKD Health Care
- Exchange
- GROW Nasdaq
- CVKD Nasdaq
- Market Cap
- GROW 31.8M
- CVKD 29.5M
- IPO Year
- GROW N/A
- CVKD 2023
- Fundamental
- Price
- GROW $2.43
- CVKD $12.71
- Analyst Decision
- GROW
- CVKD Strong Buy
- Analyst Count
- GROW 0
- CVKD 1
- Target Price
- GROW N/A
- CVKD $32.00
- AVG Volume (30 Days)
- GROW 44.9K
- CVKD 36.2K
- Earning Date
- GROW 09-09-2025
- CVKD 08-06-2025
- Dividend Yield
- GROW 3.72%
- CVKD N/A
- EPS Growth
- GROW N/A
- CVKD N/A
- EPS
- GROW 0.01
- CVKD N/A
- Revenue
- GROW $8,932,000.00
- CVKD N/A
- Revenue This Year
- GROW N/A
- CVKD N/A
- Revenue Next Year
- GROW N/A
- CVKD N/A
- P/E Ratio
- GROW $232.40
- CVKD N/A
- Revenue Growth
- GROW N/A
- CVKD N/A
- 52 Week Low
- GROW $2.02
- CVKD $5.70
- 52 Week High
- GROW $2.73
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- GROW 52.72
- CVKD 49.98
- Support Level
- GROW $2.38
- CVKD $11.00
- Resistance Level
- GROW $2.49
- CVKD $13.56
- Average True Range (ATR)
- GROW 0.09
- CVKD 1.15
- MACD
- GROW -0.01
- CVKD 0.25
- Stochastic Oscillator
- GROW 24.24
- CVKD 80.97
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.